Table 1.
Variable | HER2-low |
HER2-zero |
Overall |
p |
---|---|---|---|---|
(n = 234) | (n = 91) | (n = 325) | ||
Age (median [IQR]) | 47.0 [40.0, 53.0] | 46.0 [38.0, 54.0] | 46.0 [40.0, 53.0] | 0.6457† |
HR Status (%). | ||||
Negative | 87 (37.2) | 54 (59.3) | 141 (43.4) | 0.0005‡ |
Positive | 147 (62.8) | 37 (40.7) | 184 (56.6) | |
Grading (%). | ||||
Grade Ⅰ | 19 (8.1) | 1 (1.1) | 20 (6.2) | 0.0048※ |
Grade Ⅱ | 105 (44.9) | 29 (31.9) | 134 (41.2) | |
Grade Ⅲ | 55 (23.5) | 31 (34.1) | 86 (26.5) | |
Missing | 55 (23.5) | 30 (33.0) | 85 (26.2) | |
T stage (%). | ||||
cT1 | 10 (4.3) | 6 (6.6) | 16 (4.9) | 0.7413 |
cT2 | 130 (55.6) | 54 (59.3) | 184 (56.6) | |
cT3 | 57 (24.4) | 17 (18.7) | 74 (22.8) | |
cT4 | 33 (14.1) | 13 (14.3) | 46 (14.2) | |
Missing | 4 (1.7) | 1 (1.1) | 5 (1.5) | |
N stage (%). | ||||
cN0 | 33 (14.1) | 13 (14.3) | 46 (14.2) | 0.8319 |
cN1-3 | 198 (84.6) | 76 (83.5) | 274 (84.3) | |
Missing | 3 (1.3) | 2 (2.2) | 5 (1.5) | |
Clinical Stage (%). | ||||
1 | 2 (0.9) | 1 (1.1) | 3 (0.9) | 0.4708 |
2 | 88 (37.6) | 37 (40.7) | 125 (38.5) | |
3 | 140 (59.8) | 49 (53.8) | 189 (58.2) | |
Missing | 4 (1.7) | 4 (4.4) | 8 (2.5) | |
Histological Type (%). | ||||
No special type | 6 (2.6) | 4 (4.4) | 287 (88.3) | 0.5166 |
Invasive lobular | 206 (88.0) | 81 (89.0) | 10 (3.1) | |
Other | 22 (9.4) | 6 (6.6) | 28 (8.6) | |
AR status (%). | ||||
Positive | 115 (49.1) | 49 (53.8) | 76 (23.4) | 0.4569 |
Negative | 59 (25.2) | 17 (18.7) | 164 (50.5) | |
Missing | 60 (25.6) | 25 (27.5) | 85 (26.2) | |
Ki67 status (%). | ||||
≤20% | 67 (28.6) | 15 (16.5) | 82 (25.2) | 0.0072 |
20.1%–30.0% | 40 (17.1) | 8 (8.8) | 48 (14.8) | |
>30% | 126 (53.8) | 68 (74.7) | 194 (59.7) | |
Missing | 1 (0.4) | 0 (0.0) | 1 (0.3) |
Data are described as n (%) or median [IQR]. †Mann-Whitney test for continuous data. ‡Fisher's exact test for data with 2 categories. ※χ2 test for data with more than two categories. HR: hormone receptor; AR: androgen receptor.